Works matching DE "FEBUXOSTAT"

Results: 118

Comparison of the incidence of proteinuria and changes in eGFR among febuxostat and topiroxostat users.

Published in:

Clinical & Experimental Nephrology, 2025, v. 29, n. 6, p. 797, doi. 10.1007/s10157-025-02630-x

By:

Nakayama, Shingo;
Satoh, Michihiro;
Toyama, Maya;
Hashimoto, Hideaki;
Murakami, Takahisa;
Hirose, Takuo;
Obara, Taku;
Mori, Takefumi;
Metoki, Hirohito

Publication type:

Article

Transition Metal‐Free N−S Bond Cleavage and C−N Bond Activation of Ugi‐Adducts for Rapid Preparation of Primary Amides and α‐Ketoamides.

Published in:

Chemistry - A European Journal, 2023, v. 29, n. 53, p. 1, doi. 10.1002/chem.202301541

By:

Liu, Chao;
Van der Eycken, Johan;
Van der Eycken, Erik V.

Publication type:

Article

The Impact of Label Changes (Boxed Warning) on Real-World Febuxostat Utilization in Patients with Gout: A Cross-Sectional Drug Utilization Study.

Published in:

Rheumatology & Therapy, 2023, v. 10, n. 5, p. 1277, doi. 10.1007/s40744-023-00581-x

By:

Sosinsky, Alexandra Z.;
Song, Yufei;
Gunawardhana, Lhanoo;
Phillips, Syd;
Page, Matt

Publication type:

Article

Febuxostat Therapy for Patients with Gout and Stage 2–4 CKD: a Retrospective Study.

Published in:

Rheumatology & Therapy, 2022, v. 9, n. 5, p. 1421, doi. 10.1007/s40744-022-00480-7

By:

Zhang, Peiyu;
Chen, Mo;
Wang, Jundi;
Hu, Shunjie;
Lu, Xiaoyong;
Wu, Huaxiang

Publication type:

Article

A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout.

Published in:

Rheumatology & Therapy, 2019, v. 6, n. 4, p. 543, doi. 10.1007/s40744-019-00173-8

By:

Zhang, Fengchun;
Liu, Zhichun;
Jiang, Lindi;
Zhang, Hao;
Zhao, Dongbao;
Li, Yang;
Zou, Hejian;
Wang, Xiaoyue;
Li, Xiangpei;
Shi, Bingyin;
Xu, Jianhua;
Yang, Hongjie;
Hu, Shaoxian;
Qu, Shen

Publication type:

Article

Celebrating Versatility: Febuxostat's Multifaceted Therapeutic Application.

Published in:

Life (2075-1729), 2023, v. 13, n. 11, p. 2199, doi. 10.3390/life13112199

By:

Kraev, Krasimir Iliev;
Geneva-Popova, Mariela Gencheva;
Hristov, Bozhidar Krasimirov;
Uchikov, Petar Angelov;
Popova-Belova, Stanislava Dimitrova;
Kraeva, Maria Ilieva;
Basheva-Kraeva, Yordanka Mincheva;
Stoyanova, Nina Staneva;
Mitkova-Hristova, Vesela Todorova

Publication type:

Article

Cocrystallization of Febuxostat with Pyridine Coformers: Crystal Structural and Physicochemical Properties Analysis.

Published in:

Journal of Chemistry, 2021, p. 1, doi. 10.1155/2021/3834368

By:

Gao, Lei;
Zhang, Xianrui

Publication type:

Article

Effect of febuxostat on adverse events and mortality in gout in Taiwan: An interrupted time series analysis.

Published in:

International Journal of Rheumatic Diseases, 2023, v. 26, n. 3, p. 471, doi. 10.1111/1756-185X.14558

By:

Tsai, Ping‐Han;
Kuo, Chang‐Fu;
Liu, Jia‐Rou;
Li, Pei‐Ru;
See, Lai‐Chu

Publication type:

Article

Design, synthesis, and evaluation of the in vitro activity of novel dual inhibitors of XOR and URAT1 containing a benzoic acid group.

Published in:

Chemical Biology & Drug Design, 2023, v. 102, n. 6, p. 1553, doi. 10.1111/cbdd.14348

By:

Zhu, Xin Ying;
Chen, Hong Ming;
Zhang, Lei;
Qin, Yu Xiang;
Li, Jing

Publication type:

Article

Enhancing Febuxostat Solubility Through Cocrystal Formation: Role of Substrate Selection and Amide Coformers.

Published in:

International Journal of Molecular Sciences, 2025, v. 26, n. 7, p. 3004, doi. 10.3390/ijms26073004

By:

Pindelska, Edyta;
Sarna, Anita;
Duszczyk, Maciej;
Zep, Anna;
Madura, Izabela D.

Publication type:

Article

Efficacy and safety of febuxostat in Japanese paediatric patients with hyperuricaemia including gout: Phase 2, single arm, open‒label, multicentre studies.

Published in:

Modern Rheumatology, 2025, v. 35, n. 1, p. 194, doi. 10.1093/mr/roae056

By:

Shuichi Ito;
Yo Morita;
Makoto Nitami;
Ryutaro Iwama;
Akihiro Nakajima;
Hisashi Yamanaka;
Masataka Honda

Publication type:

Article

Evaluation of Xanthine Oxidase Inhibitors Febuxostat and Allopurinol on Kidney Dysfunction and Histological Damage in Two‐Kidney, One‐Clip (2K1C) Rats.

Published in:

Scientifica, 2025, v. 2025, p. 1, doi. 10.1155/sci5/7932075

By:

Shuvo, Asif Ul Haque;
Alimullah, Mirza;
Jahan, Ishrat;
Mitu, Kaniz Fatima;
Rahman, Md Junaeid;
Akramuddaula, Kazi;
Khan, Ferdous;
Dash, Pritesh Ranjan;
Subhan, Nusrat;
Alam, Md Ashraful;
Gorai, Sukhamoy

Publication type:

Article

Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.

Published in:

Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-07737-9

By:

Kataoka, Hiroshi;
Mochizuki, Toshio;
Ohara, Mamiko;
Tsuruta, Yuki;
Iwasa, Naomi;
Yoshida, Rie;
Tsuchiya, Ken;
Nitta, Kosaku;
Kimura, Kenjiro;
Hosoya, Tatsuo;
the FEATHER Investigators;
Steering Committee Members;
Ito, Sadayoshi;
Inaba, Masaaki;
Tomino, Yasuhiko;
Uchida, Shunya;
Makino, Hirofumi;
Matsuo, Seiichi;
Yamanaka, Hisashi;
Yamamoto, Tetsuya

Publication type:

Article

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 179, doi. 10.1002/cpdd.463

By:

Hall, Jesse;
Gillen, Michael;
Yang, Xiaojuan;
Shen, Zancong

Publication type:

Article

Retraction Note to: Anti-tumor effect of PEG-coated PLGA nanoparticles of febuxostat on A549 non-small cell lung cancer cells.

Published in:

2024

By:

Alfaifi, Mohammad Y.;
Shati, Ali A.;
Elbehairi, Serag Eldin I.;
Fahmy, Usama A.;
Alhakamy, Nabil A.;
Md, Shadab

Publication type:

Correction Notice

Effects of Febuxostat Therapy on Circulating Adipokine Profiles in Patients with Overweight or Obesity and Asymptomatic Hyperuricemia: A Randomized Controlled Study.

Published in:

Obesity Facts: The European Journal of Obesity, 2024, v. 17, n. 5, p. 524, doi. 10.1159/000540701

By:

Dong, Meijuan;
Cui, Zhaohui;
Liu, Yuanyuan;
Bu, Yanlong;
An, Kun;
Mao, Li

Publication type:

Article

Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials.

Published in:

Annals of Medicine, 2024, v. 56, n. 1, p. 1, doi. 10.1080/07853890.2024.2332956

By:

Xiu Hong Yang;
Bao Long Zhang;
Yun Cheng;
Shun Kun Fu;
Hui Min Jin

Publication type:

Article

Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis.

Published in:

International Journal of Rheumatology, 2019, p. 1, doi. 10.1155/2019/1076189

By:

Cuenca, John A.;
Balda, Javier;
Palacio, Ana;
Young, Larry;
Pillinger, Michael H.;
Tamariz, Leonardo

Publication type:

Article

A single-centre experience of febuxostat as a second-line urate-lowering therapy.

Published in:

Malaysian Family Physician, 2021, v. 16, n. 1, p. 50, doi. 10.51866/oa0892

By:

Swee Gaik Ong;
Hui Jen Ding

Publication type:

Article

C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study.

Published in:

Cardiovascular Drugs & Therapy, 2023, v. 37, n. 5, p. 965, doi. 10.1007/s10557-022-07347-7

By:

Kojima, Sunao;
Uchiyama, Kazuaki;
Yokota, Naoto;
Tokutake, Eiichi;
Wakasa, Yutaka;
Hiramitsu, Shinya;
Waki, Masako;
Jinnouchi, Hideaki;
Kakuda, Hirokazu;
Hayashi, Takahiro;
Kawai, Naoki;
Sugawara, Masahiro;
Mori, Hisao;
Tsujita, Kenichi;
Matsui, Kunihiko;
Hisatome, Ichiro;
Ohya, Yusuke;
Kimura, Kazuo;
Saito, Yoshihiko;
Ogawa, Hisao

Publication type:

Article

Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia.

Published in:

Heart & Vessels, 2020, v. 35, n. 10, p. 1446, doi. 10.1007/s00380-020-01619-8

By:

Pan, Jian-an;
Lin, Hao;
Wang, Chang-qian;
Zhang, Jun-feng;
Gu, Jun

Publication type:

Article

Development Of Immediate Release Capsule And Immediate Release Tablet Formulated Using Spray Dried Amorphous Solid Dispersion Of Febuxostat.

Published in:

International Journal of Pharmaceutical Research (09752366), 2021, v. 13, n. 2, p. 1741, doi. 10.31838/ijpr/2021.13.02.237

By:

PATEL, VAISHALI;
PATEL, ANITA;
SHAH, ASHISH

Publication type:

Article

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?

Published in:

Rheumatology / Reumatologia, 2021, v. 59, n. 6, p. 423, doi. 10.5114/reum.2021.111698

By:

Patoulias, Dimitrios Ioannis;
Doumas, Michael

Publication type:

Article

Clinical study to Evaluate Safety and Efficacy of Boozidaan (Pyrethrum indicum) in the management of Niqris Muzmin (Chronic Gout).

Published in:

Journal of Drug Delivery & Therapeutics, 2024, v. 14, n. 3, p. 8, doi. 10.22270/jddt.v14i3.6447

By:

Amin, Josee;
Islam, Naquibul;
Rafeeqi, Towseef Amin

Publication type:

Article

Effects of febuxostat on serum cytokines IL-1, IL-4, IL-6, IL-8, TNF-α and COX-2.

Published in:

Experimental & Therapeutic Medicine, 2019, v. 17, n. 1, p. 812

By:

Hao, Guohua;
Duan, Wei;
Sun, Jianping;
Liu, Jingyao;
Peng, Bo

Publication type:

Article

Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-40767-5

By:

Nata, Naowanit;
Ninwisut, Nanthawut;
Inkong, Pitchamon;
Supasyndh, Ouppatham;
Satirapoj, Bancha

Publication type:

Article

Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-40767-5

By:

Nata, Naowanit;
Ninwisut, Nanthawut;
Inkong, Pitchamon;
Supasyndh, Ouppatham;
Satirapoj, Bancha

Publication type:

Article

Preparation, optimisation, and in vitro-in vivo evaluation of febuxostat ternary solid dispersion.

Published in:

Journal of Microencapsulation, 2018, v. 35, n. 5, p. 454, doi. 10.1080/02652048.2018.1526339

By:

Tang, Jingjing;
Bao, Jiayin;
Shi, Xiangjun;
Sheng, Xiaoxia;
Su, Weike

Publication type:

Article

Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia.

Published in:

Emergency Medicine International, 2022, p. 1, doi. 10.1155/2022/1177946

By:

Liao, Zhimin;
Xu, Lei;
Wan, Bo;
Wang, Liping;
Zhao, Chengzhi;
Wu, Gang;
Xie, Rui

Publication type:

Article

A Review of Hyperuricaemia Management with Febuxostat: Dosage Titration, Monitoring and Maintenance.

Published in:

Journal of Clinical & Diagnostic Research, 2022, v. 16, n. 1, p. 7, doi. 10.7860/JCDR/2022/51970.15876

By:

RAY, DEEPAK SHANKAR;
NAIR, TINY;
DARGAD, RAMESH;
DHAR, VERINDER

Publication type:

Article

A rare case of thrombocytopenia secondary to taking febuxostat.

Published in:

Italian Journal of Medicine, 2024, v. 18, n. 2, p. 1, doi. 10.4081/itjm.2024.1724

By:

Di Zio, Isabella;
Cisternino, Rodolfo

Publication type:

Article

Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial.

Published in:

Therapeutics & Clinical Risk Management, 2023, v. 19, p. 731, doi. 10.2147/TCRM.S424598

By:

Dewi, Christiyanti;
Puspita, Falerina;
Puspitasari, Irma Melyani;
Zakiyah, Neily

Publication type:

Article

Comment on Kang et al.'s "Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis".

Published in:

American Journal of Nephrology, 2024, v. 55, n. 2, p. 260, doi. 10.1159/000533172

By:

Lai, Shih-Wei

Publication type:

Article

Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis.

Published in:

American Journal of Nephrology, 2023, v. 54, n. 3/4, p. 117, doi. 10.1159/000530972

By:

Kang, Seok Hui;
Kim, Bo Yeon;
Son, Eun Jung;
Kim, Gui Ok;
Do, Jun Young

Publication type:

Article

Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis.

Published in:

2022

By:

Zheng, Yanqun;
Sun, Jia

Publication type:

Literature Review

Effects of Valsartan in Combination with Febuxostat on Serum Uric Acid, high-sensitivity C-reactive protein and Cardiac Function of Patients with Chronic Kidney Disease Plus Hyperuricemia.

Published in:

Indian Journal of Pharmaceutical Sciences, 2020, v. 82, n. 6, p. 1054, doi. 10.36468/pharmaceutical-sciences.739

By:

CHEN WANG;
LIANGLAN SHEN;
FEN ZHANG;
XINGXING FANG;
DONGMEI CHEN;
HUAXING HUANG

Publication type:

Article

Febuxostat attenuates aluminum chloride-induced hepatorenal injury in rats with the impact of Nrf2, Crat, Car3, and MNK-mediated apoptosis.

Published in:

Environmental Science & Pollution Research, 2023, v. 30, n. 35, p. 83356, doi. 10.1007/s11356-023-28182-9

By:

Sedik, Ahmed A.;
Hassan, Soha A.;
Shafey, Heba I.;
Khalil, Wagdy K. B.;
Mowaad, Noha A.

Publication type:

Article

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients.

Published in:

Renal Failure, 2019, v. 41, n. 1, p. 595, doi. 10.1080/0886022X.2019.1632717

By:

Li, Yanchun;
Liu, Min;
Zhang, Xuelei;
Lu, Yuewu;
Meng, Juan

Publication type:

Article

Febuxostat, an inhibitor of xanthine oxidase, ameliorates ionizing radiation-induced lung injury by suppressing caspase-3, oxidative stress and NF-κB.

Published in:

Drug & Chemical Toxicology, 2022, v. 45, n. 6, p. 2586, doi. 10.1080/01480545.2021.1977315

By:

Raeispour, Marziyeh;
Talebpour Amiri, Fereshteh;
Farzipour, Soghra;
Ghasemi, Arash;
Hosseinimehr, Seyed Jalal

Publication type:

Article

Febuxostat Inhibits MPP+-Induced Inflammatory Response Through Inhibiting the JNK/NF-κB Pathway in Astrocytes.

Published in:

Neurotoxicity Research, 2021, v. 39, n. 3, p. 566, doi. 10.1007/s12640-020-00316-8

By:

Yan, Weiwei;
Zhang, Yun;
Hu, Li;
Li, Qi;
Zhou, Hongmei

Publication type:

Article

Cocrystal Prediction Based on Deep Forest Model—A Case Study of Febuxostat.

Published in:

Crystals (2073-4352), 2024, v. 14, n. 4, p. 313, doi. 10.3390/cryst14040313

By:

Chen, Jiahui;
Li, Zhihui;
Kang, Yanlei;
Li, Zhong

Publication type:

Article

Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.

Published in:

Frontiers in Endocrinology, 2023, v. 13, p. 1, doi. 10.3389/fendo.2022.1042061

By:

Takeshi Osonoi;
Miyoko Saito;
Mitsuru Hosoya;
Satako Douguchi;
Kensuke Ofuchi;
Makoto Katoh

Publication type:

Article

Identification and characterization of stress degradation products of febuxostat employing ultra‐performance liquid chromatography‐ultraviolet/photodiode array and liquid chromatography–mass spectrometry/time‐of‐flight studies

Published in:

Rapid Communications in Mass Spectrometry: RCM, 2023, v. 37, n. 2, p. 1, doi. 10.1002/rcm.9423

By:

Saha, Madhurima;
Bali, Alka;
Patra, Smruti Ranjan;
Singh, Joga

Publication type:

Article

不同剂量百令胶囊联合非布司他对慢性肾功能不全伴高尿酸血症患者肾功能及血脂水平的影响.

Published in:

Progress in Modern Biomedicine, 2020, v. 20, n. 18, p. 3572, doi. 10.13241/j.cnki.pmb.2020.18.039

By:

符薇薇;
陈洁;
陈兴强;
林丽娟;
吴琳虹;
李季芳

Publication type:

Article

非布司他治疗老年高尿酸血症痛风患者的临床疗效及安全性分析.

Published in:

Progress in Modern Biomedicine, 2019, v. 19, n. 19, p. 3780, doi. 10.13241/j.cnki.pmb.2019.19.042

By:

郭洪佩;
范俊;
路臻豪;
张爱霞;
刘伟

Publication type:

Article

非布司他对急性痛风性关节炎患者血清SUA 水平及氧化应激的影响.

Published in:

Progress in Modern Biomedicine, 2018, v. 18, n. 8, p. 1548, doi. 10.13241/j.cnki.pmb.2018.08.031

By:

肖岚;
李江涛;
李强;
李明涵;
陈芍

Publication type:

Article

Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease.

Published in:

Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-67026-1

By:

Peng, Yueh-Lung;
Tain, You-Lin;
Lee, Chien-Te;
Yang, Yi-Hsn;
Huang, Yaw-Bin;
Wen, Yen-Hsia;
Hsu, Chien-Ning

Publication type:

Article

Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia.

Published in:

Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-65706-6

By:

Omizo, Hiroki;
Tamura, Yoshifuru;
Morimoto, Chikayuki;
Ueno, Masaki;
Hayama, Yuto;
Kuribayashi-Okuma, Emiko;
Uchida, Shunya;
Shibata, Shigeru

Publication type:

Article

High-Throughput mRNA Sequencing Reveals Potential Therapeutic Targets of Febuxostat in Secondary Injury After Intracerebral Hemorrhage.

Published in:

Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.833805

By:

Wang, Xueyan;
Zhang, Chenyu;
Li, Yuwen;
Xu, Ting;
Xiang, Jin;
Bai, Yang;
Zhang, Ying;
Wang, Qi;
Zhang, Tiejun;
Liao, Linchuan

Publication type:

Article

Combination of Panax ginseng C. A. Mey and Febuxostat Boasted Cardioprotective Effects Against Doxorubicin-Induced Acute Cardiotoxicity in Rats.

Published in:

Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.905828

By:

Al-Kuraishy, Hayder M.;
Al-Hussaniy, Hany A.;
Al-Gareeb, Ali I.;
Negm, Walaa A.;
El-Kadem, Aya H.;
Batiha, Gaber El-Saber;
N. Welson, Nermeen;
Mostafa-Hedeab, Gomaa;
Qasem, Ahmed H;
Conte-Junior, Carlos Adam

Publication type:

Article